Zenlabs Ethica Limited has announced a significant change in its key managerial personnel. Ms. Manju Bala, the Company Secretary and Compliance Officer, has tendered her resignation, citing a better opportunity at another organization.

Key Details of the Resignation

Impact and Company Response

The resignation of Ms. Bala will take effect from the close of business hours on December 04, 2025. This change affects the key managerial personnel structure of Zenlabs Ethica Limited.

The Board of Directors has acknowledged Ms. Bala's contribution, expressing their appreciation for the valuable services she rendered during her tenure with the company.

Compliance and Next Steps

Zenlabs Ethica Limited has made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company will need to file the necessary forms with the Registrar of Companies, Chandigarh, to give effect to this change.

As per regulatory requirements, Ms. Bala has confirmed that there are no other material reasons for her resignation other than those mentioned in her resignation letter.

The company has not yet announced a replacement for the position of Company Secretary and Compliance Officer.

This development underscores the importance of key managerial personnel in maintaining regulatory compliance and smooth operations in listed companies.

Zenlabs Ethica Limited, a prominent player in the pharmaceutical sector, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating significant growth across key financial metrics.

Financial Highlights

The company's revenue for Q1 FY2026 stood at ₹957.50 crore, marking a substantial increase of 21.9% compared to ₹785.00 crore in the corresponding quarter of the previous year. This impressive top-line growth underscores the company's strong market position and effective business strategies.

Zenlabs Ethica's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a notable surge of 29.4%, reaching ₹212.98 crore. The EBITDA margin expanded by 130 basis points to 22.2%, reflecting improved operational efficiency and cost management.

The company's bottom line witnessed a remarkable uptick, with Profit After Tax (PAT) soaring by 50.9% to ₹131.90 crore, compared to ₹87.40 crore in the same period last year. This substantial increase in profitability demonstrates the company's ability to translate revenue growth into enhanced shareholder value.

Operational Achievements

During the quarter, Zenlabs Ethica made significant strides in its product portfolio and manufacturing capabilities:

• Launched three new products in domestic formulations, expanding its market offerings
• Filed two new Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (USFDA), showcasing the company's commitment to international market expansion
• Received approval for one generic product, further strengthening the company's product pipeline
• Commenced commercial production at the new oral solid dosage facility in Baddi, enhancing manufacturing capabilities
• Achieved 78% capacity utilization across manufacturing facilities, indicating efficient resource management

Financial Position

Zenlabs Ethica maintains a strong financial position with net cash of ₹205.98 crore, providing a solid foundation for future growth initiatives and potential investments.

Transparency and Disclosure

In line with its commitment to transparency, Zenlabs Ethica has published its financial results in the Financial Express and Dainik Tribune newspapers. The company has also implemented a QR code system, allowing stakeholders easy access to the complete financial results, demonstrating its dedication to clear and accessible financial reporting.

Conclusion

Zenlabs Ethica Limited's Q1 FY2026 results reflect a company on a strong growth trajectory, with impressive increases in revenue, profitability, and operational efficiency. The combination of new product launches, regulatory filings, and enhanced manufacturing capabilities positions the company well for sustained growth in the competitive pharmaceutical market.

Investors and stakeholders can view these results as indicative of the company's robust business model and effective execution of its growth strategies. As Zenlabs Ethica continues to expand its product portfolio and improve its operational metrics, it remains a company to watch in the pharmaceutical sector.